XML 56 R18.htm IDEA: XBRL DOCUMENT

Equity Method Investments	9 Months Ended
Equity Method Investments	Sep. 30, 2025
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	Equity Method Investments In July 2019, the Company and Bayer CropScience LP (“Bayer LP”) formed Oerth Bio LLC ("Oerth Bio"), a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. The Company and Bayer LP each held an initial ownership interest in Oerth Bio of 50%. A 15% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 43.3% and 44.3% as of September 30, 2025 and 2024, respectively, as a result of vested incentive units. Net income (loss) of Oerth Bio for the three months ended September 30, 2025 and 2024 totaled $0.2 million and $(1.2) million, respectively. Net loss of Oerth Bio for the nine months ended September 30, 2025 and 2024 totaled $0.0 million and $2.7 million, respectively. As of September 30, 2025 and 2024, the Company’s carrying value of the investment was zero. The Company also provides Oerth Bio with compensated research, development and administrative services through a separate agreement. The services rendered by the Company during the three and nine months ended September 30, 2025 and 2024 were immaterial. The Company does not anticipate rendering services in future periods.